Download PDF
Thromb Haemost 1997; 78(04): 1286-1292
DOI: 10.1055/s-0038-1657729
Rapid Communication
Schattauer GmbH Stuttgart

The Importance of Enzyme Inhibition Kinetics for the Effect of Thrombin Inhibitors in a Rat Model of Arterial Thrombosis

Margareta Elg
1   The Department of Cardiovascular Pharmacology, Mölndal, Sweden
,
David Gustafsson
1   The Department of Cardiovascular Pharmacology, Mölndal, Sweden
,
Johanna Deinum
2   The Department of Biochemistry, Astra Hässle, Mölndal, Sweden
› Author Affiliations
Further Information

Publication History

Received 27 1997

Accepted after revision 20 June 1997

Publication Date:
12 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The relation between the antithrombotic effect in vivo, and the inhibition constant (K i) and the association rate constant (k on) in vitro was investigated for eight different thrombin inhibitors. The carotid arteries of anaesthetized rats were exposed to FeCl3 for 1 h, and the thrombus size was determined from the amount of incorporated 125I- fibrinogen. The thrombin inhibitors were given intravenously, and complete concentration- and/or dose-response curves were constructed. Despite a 50,000-fold difference between the k i-values comparable plasma concentrations of hirudin and melagatran were needed (0.14 and 0.12 μmol 1-1, respectively) to obtain a 50% antithrombotic effect (IC50) in vivo. In contrast, there was a comparable in vitro (k i-value) and in vivo (IC50) potency ratio for melagatran and inogatran, respectively. These results can be explained by the concentration of thrombin in the thrombus and improved inhibition by the low-molecular-weight compounds. For all eight thrombin inhibitors tested, there was an inverse relationship between k on-values in vitro and the slope of the dose response curves in vivo. Inhibitors with k on-values of <1 X 107 M-1 s-1 gave steep dose response curves with a Hill coefficient >1. The association time for inhibition of thrombin for slow-binding inhibitors will be too long to give effective antithrombotic effects at low plasma concentrations, but at increasing concentrations the association time will decrease, resulting in a steeper dose-response curve and thereby a more narrow therapeutic interval.

 

  • References

  • 1 Badimon L, Meyer BJ, Badimon JJ. Thrombin in arterial thrombosis. Haemostasis 1994; 24 (02) 69-80
    PubMedGoogle Scholar
  • 2 Bloom AL. Physiology of blood coagulation. Haemostasis 1990; 20 (Suppl. 01) 14-29
    PubMedGoogle Scholar
  • 3 Stone SR, Tapparelli C. Thrombin inhibitors as antithrombotic agents: the importance of rapid inhibition. J Enzym Inhib 1995; 9 (01) 03-15
    PubMedGoogle Scholar
  • 4 Kettner C, Mersinger L, Knabb R. The selective inhibition of thrombin by peptides of boroarginine. J Biol Chem 1990; 265 (030) 18289-18297
    PubMedGoogle Scholar
  • 5 Nilsson T, Sjöling-Ericksson Å, Deinum J. The mechanism of binding of low-molecular weight active site inhibitors to human alpha-thrombin. Biochem J submitted
    PubMedGoogle Scholar
  • 6 Römisch J, Diehl KH, Hoffmann D, Krahl-Mateblowski U, Reers M, Stüber W, Pâques EP. Comparison of in vitro and in vivo properties of r-hirudin (HBW 023) and a synthetic analogous peptide. Haemostasis 1993; 23 (05) 249-258
    PubMedGoogle Scholar
  • 7 Bridey F, Dreyfus M, Parent F, Bros A, Fisher AM, Camez A, Simonneau G, Duroux P, Meyer D. Recombinant hirudin (HBW 023): biological data of ten patients with severe venous thrombo-embolism. Am J Hematol 1995; 49 (01) 67-72
    CrossrefPubMedGoogle Scholar
  • 8 Teger-Nilsson A, Bylund R, Gustafsson D, Gyzander E, Eriksson U. In vitro effects of inogatran, a selective LMW thrombin inhibitor. Thromb Haemost. 1997. in press
    Google Scholar
  • 9 Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, Elg M, Mattsson C, Deinum J, Pehrsson S, Karlsson O, Nilsson A, Sörensen G. Effects of melagatran, a new low molecular weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost. (To be published)
    PubMedGoogle Scholar
  • 10 Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994; 74 (01) 01-23
    CrossrefPubMedGoogle Scholar
  • 11 Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29 (030) 7095-7101
    CrossrefPubMedGoogle Scholar
  • 12 Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association. Circulation 1994; 89 (03) 1449-1468
    CrossrefPubMedGoogle Scholar
  • 13 Bush LR. Argatroban, a selective, potent thrombin inhibitor. Cardiovascular Drug Reviews 1991; 9 (03) 247-263
    CrossrefPubMedGoogle Scholar
  • 14 Kettner C, Shaw E. D-Phe-Pro-ArgCH2Cl-A selective affinity label for thrombin. Thromb Res 1979; 14 (06) 969-973
    CrossrefPubMedGoogle Scholar
  • 15 Atrash B, Jones D, Szelke M. European Patent Application 0530167A
    PubMed
  • 16 Bajusz S. Chemistry and biology of the peptide anticoagulant D-MePhe-Pro-Arg-H (GYKI-14766). Adv Exp Med Biol 1993; 340: 091-108
    PubMedGoogle Scholar
  • 17 Kikumoto R, Tamao Y, Tezuka T, Tonomura S. Selective inhibition of thrombin by (2R,4R)-4-methyl-1 -[N2-[(3-methyl-1,2,3,4-tetrahydro-8-qui- nolinyl++ +) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid. Biochemistry 1984; 23 (01) 85-90
    CrossrefPubMedGoogle Scholar
  • 18 Teger-Nilsson A, Bylund R. Preparation of peptide derivates as thrombin inhibitors. Patent Application W09311152-A1
    PubMedGoogle Scholar
  • 19 Antonsson T, Bylund R, Gustafsson D, Nilsson I. New peptide derivatives. Patent Application WO9429336-A
    PubMedGoogle Scholar
  • 20 Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60 (04) 269-280
    CrossrefPubMedGoogle Scholar
  • 21 Davies MJ, Thomas AC. Plaque fissuring-the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53 (04) 363-373
    CrossrefPubMedGoogle Scholar
  • 22 Gustafsson D, Elg M, Lenfors S, Börjesson I, Teger-Nilsson AC. Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. Blood Coagul Fibrinolysis 1996; 7 (01) 69-79
    CrossrefPubMedGoogle Scholar
  • 23 Challapalli R, Lefkovits J, Topol EJ. Clinical trials of recombinant hirudin in acute coronary syndromes. Coron Artery Dis 1996; 7: 429-437
    CrossrefPubMedGoogle Scholar
  • 24 Parry MA, Maraganore JM, Stone SR. Kinetic mechanism for the interaction of Hirulog with thrombin. Biochemistry 1994; 33 (049) 14807-14814
    CrossrefPubMedGoogle Scholar
  • 25 Witting JI, Bourdon P, Brezniak DV, Maraganore JM, Fenton JWd. Thrombin-specific inhibition by and slow cleavage of hirulog-1 [see comments]. Biochemical J 1992; 283 (Pt 3): 737-743
    CrossrefPubMedGoogle Scholar
  • 26 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86 (010) 3619-3623
    CrossrefPubMedGoogle Scholar
  • 27 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86 (02) 385-391
    CrossrefPubMedGoogle Scholar
  • 28 May RD, Hawkeswood E, Powling MJ. British Society for Haemostasis and Thrombosis. London, 12 September 1994. Abstracts Blood Coagul Fibrinolysis 1994; 5 (05) 812
    PubMedGoogle Scholar
  • 29 Gast A, Tschopp TB, Schmid G, Hilpert K, Ackermann J. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro46-6240), recombinant hirudin and heparin in human plasma. Blood Coagul Fibrinolysis 1994; 5 (06) 879-887
    CrossrefPubMedGoogle Scholar
  • 30 Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin-or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin. Thromb Haemost 1994; 72 (03) 381-386
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Bendayan P, Boccalon H, Dupouy D, Boneu B. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins. Thromb Haemost 1994; 71 (05) 576-580
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Tapparelli C, Mettemich R, Ehrhardt C, Zurini M. In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor. J Biol Chem 1993; 268 (07) 4734-4741
    PubMedGoogle Scholar
  • 33 Jackman MP, Parry MA, Hofsteenge J, Stone SR. Intrinsic fluorescence changes and rapid kinetics of the reaction of thrombin with hirudin. J Biol Chem 1992; 267 (022) 15375-15383
    PubMedGoogle Scholar